Verovaccines

Verovaccines is a German biotechnology company focused on the development of next-generation veterinary vaccines using a proprietary yeast-based platform. Spun out from the Martin Luther University Halle-Wittenberg, the company utilizes the milk yeast Kluyveromyces lactis to produce and deliver recombinant antigens. This technology allows for the creation of heat-stable, cost-effective vaccines that can be administered via various routes, including oral delivery. Their current pipeline targets major infectious diseases in livestock, such as Gumboro disease in poultry and Bovine Viral Diarrhea in cattle. By eliminating the need for complex cold chains and expensive purification processes, Verovaccines aims to transform the global animal health market. The company is supported by prominent investors including High-Tech Gründerfonds and eCAPITAL.